Patents by Inventor Phyllis L. Osheroff

Phyllis L. Osheroff has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Sensory and motor neuron derived factor (SMDF)
    Patent number: 5770567
    Abstract: Isolated SMDF, isolated DNA encoding SMDF, and recombinant or synthetic methods of preparing SMDF are disclosed. SMDF contains a .beta.-type EGF-like domain and a N-terminal sequence which is distinct from all neuregulins reported so far. SMDF, when expressed in recombinant cell culture, activates tyrosine phosphorylation of the HER2/neu receptor in human breast cancer cells and displays mitogenic activity on Schwann cells. Northern blot and in situ hybridization analysis show that SMDF differs from other neuregulins in that it is nervous tissue specific, and is very highly expressed, in comparison to other neuregulins, in the human and rat spinal cord motor neurons and sensory neurons.
    Type: Grant
    Filed: November 14, 1994
    Date of Patent: June 23, 1998
    Assignee: Genentech, Inc.
    Inventors: Wei-Hsien Ho, Phyllis L. Osheroff
  • Sensory and motor neuron derived factor (SMDF)
    Patent number: 5763213
    Abstract: Isolated SMDF, isolated DNA encoding SMDF, and recombinant or synthetic methods of preparing SMDF are disclosed. SMDF contains a .beta.-type EGF-like domain and a N-terminal sequence which is distinct from all neuregulins reported so far. SMDF, when expressed in recombinant cell culture, activates tyrosine phosphorylation of the HER2/neu receptor in human breast cancer cells and displays mitogenic activity on Schwann cells. Northern blot and in situ hybridization analysis show that SMDF differs from other neuregulins in that it is nervous tissue specific, and is very highly expressed, in comparison to other neuregulins, in the human and rat spinal cord motor neurons and sensory neurons.
    Type: Grant
    Filed: April 25, 1995
    Date of Patent: June 9, 1998
    Assignee: Genentech, Inc.
    Inventors: Wei-Hsien Ho, Phyllis L. Osheroff
  • Methods involving sensory and motor neuron derived factor (SMDF)
    Patent number: 5756456
    Abstract: A method for activating the HER2 receptor comprising contacting a cell which expresses this receptor with SMDF polypeptides is discussed. A method for enhancing differentiation and/or proliferation of a cell using SMDF polypeptides is also disclosed. These methods may be performed in vitro or in vivo.
    Type: Grant
    Filed: April 25, 1995
    Date of Patent: May 26, 1998
    Assignee: Genentech, Inc.
    Inventors: Wei-Hsien Ho, Phyllis L. Osheroff
  • Antibodies to SMDF
    Patent number: 5667780
    Abstract: Isolated SMDF, isolated DNA encoding SMDF, and antibodies to SMDF are disclosed. SMDF contains a .beta.-type EGF-like domain and a N-terminal sequence which is distinct from all neuregulins reported so far. SMDF, when expressed in recombinant cell culture, activates tyrosine phosphorylation of the HER2/neu receptor in human breast cancer cells and displays mitogenic activity on Schwann cells. Northern blot and in situ hybridization analysis show that SMDF differs from other neuregulins in that it is nervous tissue specific, and is very highly expressed, in comparison to other neuregulins, in the human and rat spinal cord motor neurons and sensory neurons.
    Type: Grant
    Filed: April 25, 1995
    Date of Patent: September 16, 1997
    Assignee: Genentech, Inc.
    Inventors: Wei-Hsien Ho, Phyllis L. Osheroff
  • Use of relaxin in the treatment of bradycardia
    Patent number: 5478807
    Abstract: The invention concerns the use of relaxin or another compound capable of specific binding of a relaxin receptor in the heart in the cardiovascular therapy, and specifically in the treatment of acute and chronic heart failure or of a condition characterized by pathologically low heart rate. The invention further concerns the treatment of neurodegenerative diseases using relaxin or other compounds capable of selectively binding a relaxin receptor in the brain.
    Type: Grant
    Filed: June 23, 1992
    Date of Patent: December 26, 1995
    Assignee: Genentech, Inc.
    Inventors: Michael Cronin, Phyllis L. Osheroff, G. Roger Thomas, David G. Ward
  • Use of relaxin in cardiovascular therapy
    Patent number: 5166191
    Abstract: The invention concerns the use of relaxin in the cardiovascular therapy, and specifically in the treatment of acute and chronic heart failure.
    Type: Grant
    Filed: August 19, 1991
    Date of Patent: November 24, 1992
    Assignee: Genentech, Inc.
    Inventors: Michael Cronin, Phyllis L. Osheroff, David G. Ward